Number №4, 2019 - page 40-46

Results of evaluating the influence of a herbal drug with a complex of biologically active components on the biochemical indicators of urine in patients with urolithiasis DOI: 10.29188/2222-8543-2019-11-4-40-46

For citation: Prosyannikov M.Yu., Mazurenko D.A., Konstantinova O.V., Shaderkin I.A., Golovanov S.A., Anokhin N.V., Voitko D.A. Results of evaluating the influence of a herbal drug with a complex of biologically active components on the biochemical indicators of urine in patients with urolithiasis. Experimental and clinical urology 2019;(4):40-46
Prosyannikov M.Yu., Mazurenko D.A., Konstantinova O.V., Shaderkin I.A., Golovanov S.A., Anohin N.V., Voytko D.A.
Information about authors:
  • Prosyannikov M.Yu. – PhD, Head of Department of urolithiasis of N.A. Lopatkin Scientific Research Institute of Urology and Interventional Radiology – Branch of the National Medical Research Centre of Radiology of the Ministry of Health of Russian Federation, prosyannikov@gmail.com, ORCID 0000-0003-3635-5244
  • Mazurenko D.A. – PhD, Associate Professor at the Department of Urology and Andrology of the Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency,Uro1@inbox.ru
  • Konstantinova O.V. – Dr. Sc., Chief Researcher at the Department of urolithiasis of N.A. Lopatkin Scientific Research Institute of Urology and Interventional Radiology – Branch of the National Medical Research Centre of Radiology of the Ministry of Health of Russian Federation, konstant-ov@yandex.ru, ORCID 0000-0002-2214-7543
  • Shaderkin I.A. – PhD, Head of the Laboratory of Electronic Health, Institute of Digital Medicine, Sechenov University, info@uroweb.ru, ORCID 0000-0001-8669-2674
  • Golovanov S.A. – Dr. Sc., head of scientific Laboratory Department of N.A. Lopatkin Scientific Re- search Institute of Urology and Interventional Radiology – Branch of the National Medical Research Radiological Centre of the Ministry of Health of Russian Federation, sergeygol124@mail.ru, ORCID 0000-0002-6516-4730
  • Anokhin N.V. – PhD, Researcher of the Department of urolithiasis of N.A. Lopatkin Scientific Re- search Institute of Urology and Interventional Radiology – Branch of the National Medical Research Centre of Radiology of the Ministry of Health of Russian Federation, anokhinnikolay@yandex.ru, ORCID 0000-0002-4341-4276
  • Voytko D.A. – PhD, Researcher of the Department of urolithiasis of N.A. Lopatkin Scientific Research Institute of Urology and Interventional Radiology – Branch of the National Medical Research Centre of Radiology of the Ministry of Health of Russian Federation, 1987vda@mail.ru, ORCID 0000-0003-1292-1651
195

Introduction. Prevention of relapse of calcium-oxalate urolithiasis is challenging. Diet as the first stage of prevention does not always allow to achieve remission. Herbal preparations are widely used as alternative treatment. One of these drugs is Oxalit – a biologically active complex.

Purpose. The evaluation of the impact of the «Oxalit» complex on metabolic parameters in patients with urolithiasis, and the determination of the possibilities of its use in the treatment of patients with calcium-oxalate urolithiasis.

Materials and methods. A clinical study of the biologically active complex «Oxalit» was conducted. The study involved 60 patients with urolithiasis: the treatment arm included 30 patients who received «Oxalit» for 90 days with diet recommendations. The control arm consisted of 30 patients with urolithiasis received only diet recommendations for 90 days.

Results and discussion. In the treatment group (Oxalit), a 2.4-fold decrease in renal excretion of oxalates and an increase in urinary excretion of magnesium by 53.4% were noted. The level of hematuria, leukocyturia and proteinuria was almost 3 times lower. However, urinary glucose excretion in- creased. There were no statistical changes in renal daily excretion of sodium, inorganic phosphates, citrates, urea, chlorine, bilirubin, and urine output.

Conclusions. The biologically active complex «Oxalit» can be recommended in the treatment of calcium-oxalate urolithiasis as an anti-relapse drug.

Conflict of interest. The authors declare no conflict of interest.

AttachmentSize
Download423.25 KB
urolithiasis, metabolic disorders, herbal medicine, Oxalit

Readera - Социальная платформа публикаций

Crossref makes research outputs easy to find, cite, link, and assess